C.M. Bidwell & Associates’s 10x Genomics TXG Stock Holding History

C.M. Bidwell & Associates’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$255	Hold	12	–	–	﹤0.01%	473
2025 Q4	$196	Hold	12	–	–	﹤0.01%	478
2025 Q3	$140	Hold	12	–	–	﹤0.01%	483
2025 Q2	$139	Hold	12	–	–	﹤0.01%	441
2025 Q1	$105	Hold	12	–	–	﹤0.01%	437
2024 Q4	$172	Sell	12 -60	-83%	-$947	﹤0.01%	480
2024 Q3	$1.63K	Hold	72	–	–	﹤0.01%	439
2024 Q2	$1.4K	Hold	72	–	–	﹤0.01%	417
2024 Q1	$2.7K	Hold	72	–	–	﹤0.01%	401
2023 Q4	$4.03K	Hold	72	–	–	﹤0.01%	345
2023 Q3	$2.97K	Hold	72	–	–	﹤0.01%	415
2023 Q2	$4.02K	Hold	72	–	–	﹤0.01%	409
2023 Q1	$4.02K	Hold	72	–	–	﹤0.01%	402
2022 Q4	$2.62K	Buy	+72	New	+$2.35K	﹤0.01%	414
2022 Q3	–	Sell	-12	Closed	-$1K	–	544
2022 Q2	$1K	Hold	12	–	–	﹤0.01%	478
2022 Q1	$1K	Buy	+12	New	+$1.05K	﹤0.01%	515

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

C.M. Bidwell & Associates's TXG Position: Q1 2026 in Review

C.M. Bidwell & Associates held its 10x Genomics (TXG) position steady in Q1 2026 at 12 shares worth $255. The position accounts for ﹤0.01% of the portfolio, ranked #473.

C.M. Bidwell & Associates first reported a position in TXG in Q1 2022 and has held it in 16 quarters since. The position peaked at $4.03K in Q4 2023. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

C.M. Bidwell & Associates held 12 shares of 10x Genomics worth $255 as of Q1 2026.
C.M. Bidwell & Associates left its 10x Genomics share count unchanged in Q1 2026.
10x Genomics made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q1 2026, its #473 holding.
C.M. Bidwell & Associates first reported a position in 10x Genomics in Q1 2022 and has held it in 16 quarters since.
C.M. Bidwell & Associates's 10x Genomics position peaked at $4.03K in Q4 2023.
329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.